BICYCLE THERAPEUTICS PLC Income Statement
BCYC|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$73M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$247M
FY2025
Net Income
-$219M
FY2025
BICYCLE THERAPEUTICS PLC reported $73M in revenue and $219M in net loss for FY2025. Revenue has grown at a 31.9% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.98 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
- Negative return on equity: -35.9% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M |
| SG&A Expense | $79.4M | $72.2M | $60.4M | $49.5M | $32.4M | $29.2M | $14.6M |
| R&D Expense | $240.3M | $173.0M | $156.5M | $81.6M | $44.9M | $33.1M | $25.5M |
| Operating Income | -$247.1M | -$209.9M | -$189.9M | -$116.7M | -$65.6M | -$52.0M | -$26.3M |
| Interest Expense | - | - | $3.3M | $3.3M | $3.0M | $457.0K | - |
| Income Tax | $152.0K | -$4.8M | $1.5M | -$1.5M | -$1.7M | -$724.0K | -$254.0K |
| Net Income | -$219.0M | -$169.0M | -$180.7M | -$112.7M | -$66.8M | -$51.0M | -$30.6M |
| EPS (Basic) | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | - | - |
| EPS (Diluted) | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | -$49.78 | -$48.81 |
| Shares Outstanding | 69.1M | 42.4M | 29.9M | 29.6M | 21.1M | 18.0M | 814.7K |
| Operating Margin | -340.4% | -595.0% | -704.1% | -806.6% | -561.0% | -500.1% | -190.6% |
| Profit Margin | -301.7% | -479.2% | -669.7% | -779.4% | -571.3% | -491.0% | -221.8% |